Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants: A systematic review and meta-analysis

CNS Drugs

Volumn 22, Issue 7, 2008, Pages 587-602

  Nakagawa, Atsuo ^a   Watanabe, Norio ^b   Omori, Ichiro M ^b   Barbui, Corrado ^c   Cipriani, Andrea ^c   McGuire, Hugh ^d   Churchill, Rachel ^d   Furukawa, Toshi A ^b  

^a KEIO UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c UNIVERSITY OF VERONA   (Italy)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Amitriptyline, therapeutic use; Antidepressants, therapeutic use; Clomipramine, therapeutic use; Depression, treatment; Fluoxetine, therapeutic use; Fluvoxamine, therapeutic use; Imipramine, therapeutic use; Meta analysis; Mianserin, therapeutic use

Indexed keywords

AMITRIPTYLINE; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIANSERIN; MILNACIPRAN; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

CINAHL; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MEDLINE; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSYCINFO; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; DRUG EVALUATION; HUMANS; META-ANALYSIS AS TOPIC; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 44949128357     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822070-00004     Document Type: Review

References (91)

1. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157 Suppl. 4: 1-45
2. Ellis P. Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust N Z J Psychiatry 2004 Jun; 38 (6): 389-407
3. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. London: National Institute for Clinical Excellence, 2004
4. Barbui C, Hotopf M, Freemantle N, et al. Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst Rev 2000; (4): CD 002791
5. McManus P, Mant A, Mitchell PB, et al. Recent trends in the use of antidepressants in Australia, 1990-1998. Med J Aust 2000 Nov 6; 173 (9): 458-61
6. Olfson M, Marcus SC, Pincus HA, et al. Antidepressant prescribing practices of outpatient psychiatrists. Arch Gen Psychiatry 1998 Apr; 55 (4): 310-6
7. Lawrenson RA, Tyrer F, Newson RB, et al. The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 2000 Aug; 59 (2): 149-57
8. Rihmer Z. Can better recognition and treatment of depression reduce suicide rates? A brief review. Eur Psychiatry 2001 Nov; 16 (7): 406-9
9. Nakagawa A, Grunebaum MF, Ellis SP, et al. Association of suicide and antidepressant prescription rates in Japan, 1999-2003. J Clin Psychiatry 2007; 68 (6): 908-16
10. Moret C, Charveron M, Finberg JPM, et al. Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbony-l-2-aminomethyl- cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 1985; 24 (12): 1211-9
11. Briley M, Prost J, Moret C. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol 1996; 11 Suppl. 4: 9-14
12. Puozzo C, Leonard BE. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 1996; 11 Suppl. 4: 15-27
13. Sawada Y, Ohtani H. Pharmacokinetics and drug interactions of antidepressive agents [in Japanese]. Nippon Rinsho 2001; 59 (8): 1539-45
14. Puozzo C, Lens S, Reh C, et al. Lack of interaction of milnacipran with the cytochrome P450 isoenzymes frequently involved in antidepressant metabolism. Clin Pharmacokinet 2005; 44 (9): 977-88
15. Tignol J, Pujol-Domenech J, Chartres JP, et al. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Acta Psychiatr Scand 1998; 97 (2): 157-65
16. Van Amerongen AP, Ferrey G, Tournoux A. A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression. J Affect Disord 2002; 72 (1): 21-31
17. Lopez-Ibor JJ, Conesa A. A comparative study of milnacipran and imipramine in the treatment of major depressive disorder. Spanish Milnacipran/Imipramine Study. Curr Med Res Opin 2004; 20 (6): 855-60
18. Leinonen E, Lepola U, Koponen H, et al. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Acta Psychiatr Scand 1997; 96 (6): 497-504
19. Guelfi JD, Ansseau M, Corruble E, et al. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int Clin Psychopharmacol 1998; 13 (3): 121-8
20. Clerc G. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Milnacipran/Fluvoxamine Study Group. Int Clin Psychopharmacol 2001; 16 (3): 145-51
21. Sechter D, Vandel P, Weiller E, et al. A comparative study of milnacipran and paroxetine in outpatients with major depression. J Affect Disord 2004; 83 (2-3): 233-6
22. Ansseau M, Papart P, Troisfontaines B, et al. Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology (Berl) 1994; 114 (1): 131-7
23. Puech A, Montgomery SA, Prost JF, et al. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 1997; 12 (2): 99-108
24. Papakostas GI, Fava M. A meta-analysis of clinical trials comparing milnacipran, a serotonin-norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Eur Neuropsychopharmacol 2007; 17 (1): 32-6
25. Cipriani A, Brambilla P, Furukawa T, et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 2005; (4): CD004185
26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
27. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., revised. Washington, DC: American Psychiatric Association, 1987
28. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
29. World Health Organization. International statistical classification of diseases and health related problems. 10th rev. Geneva: World Health Organization, 1992
30. Feighner JP, Robins E, Guze SB, et al. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry 1972; 26 (1): 57-63
31. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry 1978; 35 (6): 773-82
32. Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions 4.2.5 [updated May 2005]. In: The Cochrane library, issue 3. Chichester: John Wiley & Sons Ltd, May 2005
33. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
34. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9
35. Furukawa TA, Akechi T, Azuma H, et al. Evidence-based guidelines for interpretation of the Hamilton Rating Scale for Depression (HAM-D). J Clin Psychopharmacol 2007; 27 (5): 531-4
36. Furukawa TA, Watanabe N, Omori IM, et al. Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. JAMA 2007; 297 (5): 468-70
37. Lecrubier Y, Pletan Y, Solles A, et al. Clinical efficacy of milnacipran: placebo-controlled trials. Int Clin Psychopharmacol 1996; 11 Suppl. 4: 29-33
38. Lopez-Ibor J, Guelfi JD, Pletan Y, et al. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 1996; 11 Suppl. 4: 41-6
39. Okamura K, Furukawa TA. Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression. Clin Drug Investig 2006; 26 (3): 135-42
40. Furukawa TA, Cipriani A, Barbui C, et al. Imputing response rates from means and standard deviations in meta-analysis. Int Clin Psychopharmacol 2005; 20 (1): 49-52
41. Furukawa TA, Barbui C, Cipriani A, et al. Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiology 2006; 59 (1): 7-10
42. Boissel JP, Cucherat M, Li W, et al. The problem of therapeutic efficacy indices: 3. Comparison of the indices and their use [in French]. Therapie 1999; 54 (4): 405-11
43. Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol 2002; 31 (1): 72-6
44. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414): 557-60
45. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med 1992; 116 (1): 78-84
46. Review Manager (RevMan) [computer program]. Version 4.2 for Windows. Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2003
47. Matsubara R, Onodera I, Ito K, et al. A double-blind comparison of milnacipran and imipramine in depressive patients. XXth Collegium Internationale Neuropsychopharmacologicum; 1996 Jun 23-27; Melbourne (VIC)
48. Baek HK, Yu BH. The effect of antidepressant treatment on beta-adrenergic receptor responsiveness in patients with major depression [abstract]. Int J Neuropsychopharmacol 2002; 5 Suppl. 1: 148
49. Lee MS, Ham BJ, Kee BS, et al. A comparison of the efficacy and safety between milnacipran and fluoxetine in the treatment of patients with depression [abstract]. Int J Neuropsychopharmacol 2002; 5 Suppl. 1: 205
50. Lee MS, Ham BJ, Kee BS, et al. The efficacy and safety of milnacipran in patients with major depression: a comparison with fluoxetine. J Korean Neuropsychiatr Assoc 2004; 43 (4): 415-24
51. Macher JP, Sichel JP, Serre C, et al. Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology 1989; 22 (2): 77-82
52. Kanemoto K, Matsubara M, Yamashita K, et al. Controlled comparison of two different doses of milnacipran in major depressive outpatients. Int Clin Psychopharmacol 2004; 19 (6): 343-6
53. Wyeth. Phase III multi-center, double-blind, comparative study of Effexor XR for the treatment of depression. ClinicalTrials. gov identifier NCT00225511 [online]. Available from URL: http://clinicaltrials.gov/ct/show/NCT00225511 [Accessed 2008 May 17]
54. Baek HK, Kim EJ, Yu BH. The effect of antidepressant treatment on beta-adrenergic receptor responsiveness in patients with major depression. Korean J Psychopharmacol 2003; 13 (3): 154-63
55. Rouillon F, Berdeaux G, Bisserbe JC, et al. Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life. J Affect Disord 2000; 58 (3): 171-80
56. Ansseau M, von Frenckell R, Mertens C, et al. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Psychopharmacology (Berl) 1989; 98 (2): 163-8
57. Ansseau M, Von Frenckell R, Papart P, et al. Controlled major parison of milnacipran (F2207) 200mg and amitriptyline in endogenous depressive inpatients. Hum Psychopharmacol 1989; 4: 221-7
58. Yamashita I, Matubara R, Onodera I, et al. Clinical evaluation of milnacipran hydrochloride (tn-912) on depression and depressive states: phase III clinical trial with imipramine hydrochloride as a control drug. Rinsyoiyaku 1995; 11 (4): 819-42
59. Ansseau M, von Frenckell R, Gerard MA, et al. Interest of a loading dose of milnacipran in endogenous depressive inpatients: comparison with the standard regimen and with fluvoxamine. Eur Neuropsychopharmacol 1991; 1 (2): 113-21
60. Lee MS, Ham BJ, Kee BS, et al. Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression. Curr Med Res Opin 2005; 21 (9): 1369-75
61. Shinkai K, Yoshimura R, Ueda N, et al. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J Clin Psychopharmacol 2004; 24 (1): 11-7
62. Yang JC, Kim SW, Yu BH. Milnacipran versus sertraline in major depressive disorder: a double-blind randomized comparative study on the treatment effect and cbeta-adrenergic receptor responsiveness. Korean J Psychopharmacol 2003; 14 (4): 387-96
63. Endo S, Miura S, Miyasaka M, et al. Clinical evaluation of milnacipran hydrochloride, a new antidepressant for depression and depressive state phase III clinical trials with mianserin hydrochloride as a control drug. Clin Eval 1995; 23 (1): 39-64
64. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999; 354 (9193): 1896-900
65. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178: 234-41
66. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002; 180: 396-404
67. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002; 63 (3): 225-31
68. Cowen PJ, Ogilvie AD, Gama J. Efficacy, safety and tolerability of duloxetine 60mg once daily in major depression. Curr Med Res Opin 2005; 21 (3): 345-56
69. Frampton JE, Plosker GL. Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs 2007; 21 (7): 581-609
70. Lopez-Ibor J, Guelfi JD, Pletan Y, et al. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 1996; 11 Suppl. 4: 41-6
71. von Frenckell R, Ansseau M, Serre C, et al. Pooling two controlled comparisons of milnacipran (F2207) and amitriptyline in endogenous inpatients: a new approach in dose ranging studies. Int Clin Psychopharmacol 1990 Jan; 5 (1): 49-56
72. Bollini P, Pampallona S, Tibaldi G, et al. Effectiveness of antidepressants: meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry 1999; 174: 297-303
73. Adli M, Baethge C, Heinz A, et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005; 255 (6): 387-400
74. Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998; 7 Suppl. 1: 11-7
75. Tzanakaki M, Guazzelli M, Nimatoudis I, et al. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Int Clin Psychopharmacol 2000; 15 (1): 29-34
76. Barbui C, Guaiana G, Hotopf M. Amitriptyline for inpatients and SSRIs for outpatients with depression? Systematic review and meta-regression analysis. Pharmacopsychiatry 2004; 37 (3): 93-7
77. Sugawara Y, Higuchi H, Yoshida K, et al. Response rate obtained using milnacipran depending on the severity of depression in the treatment of major depressive patients. Clin Neuropharmacol 2006; 29 (1): 6-9
78. Papakostas GI, Thase ME, Fava M, et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007; 62 (11): 1217-27
79. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58 (1): 19-36
80. Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 1997; 6 (1): 10-8
81. Montgomery SA. A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. Int Clin Psychopharmacol 2001; 16 (3): 169-78
82. Geddes JR, Freemantle N, Mason J, et al. SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev 2000; (2): CD001851
83. MacGillivray S, Arroll B, Hatcher S, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 2003; 326 (7397): 1014
84. Anderson IM. Meta-analytical studies on new antidepressants. Br Med Bull 2001; 57: 161-78
85. Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005; 143 (6): 415-26
86. Chan AW, Hrobjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004; 291 (20): 2457-65
87. Chan AW, Altman DG. Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ 2005; 330 (7494): 753
88. Heres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006; 163 (2): 185-94
89. Perlis RH, Perlis CS, Wu Y, et al. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry 2005; 162 (10): 1957-60
90. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003; 289 (4): 454-65
91. Bhandari M, Busse JW, Jackowski D, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 2004; 170 (4): 477-80